Skip to main
PEPG
PEPG logo

PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen Inc (PEPG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

PepGen Inc. has presented encouraging initial data from the FREEDOM-DM1 trial, demonstrating a dose-dependent increase in splicing correction, with nearly a four-fold efficacy increase observed from 5 mg/kg to 10 mg/kg doses, thus validating its Enhanced Delivery Oligonucleotide (EDO) platform. The company’s efforts to advance its lead product, PGN-EDODM1, indicate significant potential for therapeutic benefits, as evidenced by a splicing correction of 29.1%, surpassing the established benchmark for clinical relevance. Moreover, the absence of safety issues during trials provides a robust foundation for continued optimism about PepGen’s pipeline products and overall strategy in the neuromuscular disease therapeutic landscape.

Bears say

PepGen reported a significant net loss of $22 million or $0.68 per share for the fourth quarter of 2024, raising concerns about its financial sustainability amid ongoing clinical challenges. The company's probability of success for its lead product, PGN-EDO51, has been reduced from 40% to 25% due to safety concerns related to kidney function issues and the risk of clinical failures, which may impact regulatory approval in key markets such as the US and EU. Additionally, there are uncertainties regarding PGN-EDO51's ability to achieve peak commercial revenue, compounded by potential market size limitations and penetration rates, further contributing to a negative outlook for the stock.

PepGen Inc (PEPG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PepGen Inc (PEPG) Forecast

Analysts have given PepGen Inc (PEPG) a Buy based on their latest research and market trends.

According to 5 analysts, PepGen Inc (PEPG) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PepGen Inc (PEPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.